Undisputed HBM leader (~57% share), capacity fully booked through 2027–2028. At ~6x forward earnings it's priced as if the cycle ends tomorrow — yet the supply thesis says it runs 2+ more years. Purest single-name exposure to the AI-memory bottleneck.
The laggard catching up — trailed Hynix on HBM qualification, so it re-rated later and sits at the cheapest forward multiple here (~5x). Diversification (foundry, phones, displays) is a margin of safety, plus optionality if HBM4 wins more NVIDIA share.
Cleanest, most liquid US way to own the cycle. Up ~273% YTD, but at <9x forward the multiple compressed as estimates raced higher. Only Western firm with HBM + DRAM + NAND under one roof. The "obvious" pick that's paradoxically not overpriced on forward math.
Pure-play NAND/storage spun out of WD, levered straight to NAND ASPs (+55–75% forecast 2026) and enterprise-SSD demand (+86% QoQ in Q1'26). Extreme momentum (+623% YTD) = high risk, but ~11x forward isn't rich if NAND stays sold out.
Leading NAND-flash controller designer — picks-and-shovels for every SSD/UFS module. Rides SSD volume + content growth; BofA target lifted to $450. Risk: extreme NAND prices can crimp module-maker demand. Less of a slam-dunk than the producers.
AI-memory integrator (Integrated Memory, MemoryAI, CXL, AI-factory deployments) sitting in the inference memory bottleneck — Q1'26 sales $343M, FY26 guide raised to high end. Not a household name, so it hasn't been bid to the moon. $108 street target (~31x FY27 EPS $3.51) = ~58% upside. The most genuinely reasonably-valued growth name here.
Largest independent photomask maker — every new memory node and capacity expansion needs masks. Deepest-value, most overlooked supplier here (low-teens P/E vs 40–50x for other equipment). Lower beta to the mania, but a steady toll-taker on the capex wave Nanya/Winbond/Micron are now unleashing.
Nanya 2408.TW — fwd ~7.8x, revenue +649%, repeated limit-up (NT$454). DDR4/legacy-DRAM squeeze beneficiary. · Winbond 2344.TW — fwd ~7.2x (NT$211), niche DRAM/flash; MS target NT$100→222. Both cheap on forward but have run vertically — treat as trades, not value entries.
FormFactor (FORM) fwd ~51x · Lam 47x · Applied 36x · KLA 49x · ACM Research 44x · Onto 32x · Camtek 38x · Teradyne 45x · Advantest very high — good businesses, none "undervalued." Aehr (AEHR) fwd ~688x and Netlist (NLST) no earnings ($2.68, an IP-litigation lottery ticket) — speculative, not value.
Multiples move daily — re-check before acting. Snapshot data via yfinance, 23–24 Jun 2026. Sources: TrendForce, BofA, Morgan Stanley, CNBC, company filings.